Dapagliflozin [10 mg film-coated tablet] for use as add-on treatment to metformin (MET) for adults with Type 2 Diabetes Mellitus (T2DM) who have or are at a high risk of having cardiovascular disease and/or diabetic nephropathy
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 24 March 2023)
The HTA Council recommends the government financing of dapagliflozin [10 mg film-coated tablet] for use as add-on treatment to metformin (MET) for adults with Type 2 Diabetes Mellitus (T2DM) who have or are at a high risk of having cardiovascular disease and/or diabetic nephropathy through its inclusion in the Philippine National Formulary.
Relevant Information
- Status: With Final HTA Council Recommendation
- Topic Assignment: Internal Assessment
- Policy Question: Should dapagliflozin be included in the Philippine National Formulary for the treatment of Type 2 Diabetes Mellitus as second-line therapy after metformin?
- Secretary of Health Decision: Approved as of 11 April 2023
Evidence and Relevant Documents